Home » Authors » Brady Huggett

Articles by Brady Huggett

Peregrine Gets FDA OK For Cotara Phase III, Awaits Partner

Feb. 25, 2003

By Brady Huggett

Peregrine Gets FDA OK For Cotara Phase III, Awaits Partner

Feb. 25, 2003

By Brady Huggett

BioMarin Raises $75M Publicly, Gets Good News On Aldurazyme

Feb. 24, 2003

By Brady Huggett

BioMarin Raises $75M Publicly, Gets Good News On Aldurazyme

Feb. 24, 2003

By Brady Huggett

Biogen's Amevive Shot Down In Europe; Approval Years Away

Feb. 21, 2003

By Brady Huggett

SomaLogic Raises $19.5M To Develop Proteomics Products

Feb. 21, 2003

By Brady Huggett

Biogen's Amevive Shot Down In Europe; Approval Years Away

Feb. 21, 2003

By Brady Huggett

SomaLogic Raises $19.5M To Develop Proteomics Products

Feb. 21, 2003

By Brady Huggett

BattellePharma Raises $22M To Develop Inhalation Program

Feb. 20, 2003

By Brady Huggett

BattellePharma Raises $22M To Develop Inhalation Program

Feb. 20, 2003

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for April 15, 2025.
Biopharma exempt from US reciprocal tariffs, but not untouched
BioWorld
At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...
ADPD 2025: Unlocking GLP-1's potential in neurodegeneration
BioWorld
At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...
ADPD 2025: Novel treatment modalities in neurodegenerative disorders
BioWorld Science
The current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease...